Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Neurocrine Bioscienc (NBIX)
Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,449,305
  • Shares Outstanding, K 98,252
  • Annual Sales, $ 1,489 M
  • Annual Income, $ 154,500 K
  • 60-Month Beta 0.41
  • Price/Sales 7.73
  • Price/Cash Flow 65.73
  • Price/Book 5.75
Trade NBIX with:

Options Overview Details

View History
  • Implied Volatility 25.53% ( +0.18%)
  • Historical Volatility 26.90%
  • IV Percentile 17%
  • IV Rank 24.50%
  • IV High 43.87% on 01/09/23
  • IV Low 19.58% on 08/30/23
  • Put/Call Vol Ratio 0.03
  • Today's Volume 30
  • Volume Avg (30-Day) 366
  • Put/Call OI Ratio 1.25
  • Today's Open Interest 11,010
  • Open Int (30-Day) 11,811

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 1.11
  • Number of Estimates 11
  • High Estimate 1.38
  • Low Estimate 0.42
  • Prior Year 0.88
  • Growth Rate Est. (year over year) +26.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.63 +13.36%
on 11/10/23
118.03 -0.47%
on 12/04/23
+5.03 (+4.47%)
since 11/03/23
3-Month
103.63 +13.36%
on 11/10/23
119.29 -1.53%
on 09/12/23
+7.54 (+6.86%)
since 09/05/23
52-Week
89.04 +31.93%
on 05/30/23
125.25 -6.21%
on 12/06/22
-6.53 (-5.27%)
since 12/05/22

Most Recent Stories

More News
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 117.53 (+0.86%)
Pharma Showdown: Evaluating Neurocrine Biosciences (NBIX) and Vaxcyte (PCVX) Stock Performance Under the Microscope

The pharmaceutical landscape is evolving in response to the shift toward sedentary living and is driven by substantial investments in R&D and advanced technologies. Against this backdrop, which of the...

NBIX : 117.53 (+0.86%)
PCVX : 54.59 (+0.76%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and...

NBIX : 117.53 (+0.86%)
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

CAHtalyst™ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and...

NBIX : 117.53 (+0.86%)
3 A-Rated Pharma Buys for October

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks...

AZN : 64.21 (-1.25%)
NBIX : 117.53 (+0.86%)
NVO : 99.81 (-1.10%)
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the...

NBIX : 117.53 (+0.86%)
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application...

NBIX : 117.53 (+0.86%)
3 A-Rated Pharma Stocks to Buy Today

The pharmaceutical industry is expected to grow in the upcoming years, propelled by continual advancements in medicine, aiming to meet the escalating demands for chronic disease treatment and address the...

ABBV : 145.00 (+0.59%)
NBIX : 117.53 (+0.86%)
NVO : 99.81 (-1.10%)
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive top-line data from the Phase 3 CAHtalyst™ Adult Study evaluating the...

NBIX : 117.53 (+0.86%)
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the...

NBIX : 117.53 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 120.25
2nd Resistance Point 119.14
1st Resistance Point 117.83
Last Price 117.53
1st Support Level 115.42
2nd Support Level 114.31
3rd Support Level 113.01

See More

52-Week High 125.25
Last Price 117.53
Fibonacci 61.8% 111.42
Fibonacci 50% 107.15
Fibonacci 38.2% 102.87
52-Week Low 89.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar